Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2007 1
2009 1
2010 1
2011 1
2014 1
2015 2
2016 2
2018 2
2019 2
2020 3
2021 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
Xu Y, Carrascosa LC, Yeung YA, Chu ML, Yang W, Djuretic I, Pappas DC, Zeytounian J, Ge Z, de Ruiter V, Starbeck-Miller GR, Patterson J, Rigas D, Chen SH, Kraynov E, Boor PP, Noordam L, Doukas M, Tsao D, Ijzermans JN, Guo J, Grünhagen DJ, Erdmann J, Verheij J, van Royen ME, Doornebosch PG, Feldman R, Park T, Mahmoudi S, Dorywalska M, Ni I, Chin SM, Mistry T, Mosyak L, Lin L, Ching KA, Lindquist KC, Ji C, Londono LM, Kuang B, Rickert R, Kwekkeboom J, Sprengers D, Huang TH, Chaparro-Riggers J. Xu Y, et al. Among authors: yeung ya. Cancer Immunol Res. 2021 Oct;9(10):1141-1157. doi: 10.1158/2326-6066.CIR-21-0058. Epub 2021 Aug 10. Cancer Immunol Res. 2021. PMID: 34376502
CD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus.
Andreata F, Moynihan KD, Fumagalli V, Di Lucia P, Pappas DC, Kawashima K, Ni I, Bessette PH, Perucchini C, Bono E, Giustini L, Nguyen HC, Chin SM, Yeung YA, Gibbs CS, Djuretic I, Iannacone M. Andreata F, et al. Among authors: yeung ya. Sci Transl Med. 2024 Jan 10;16(729):eadi1572. doi: 10.1126/scitranslmed.adi1572. Epub 2024 Jan 10. Sci Transl Med. 2024. PMID: 38198572
IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity.
Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, Bessette P, Lan RY, Nguyen HC, Mathewson ND, Ni I, Chen W, Lee Y, Liao-Chan S, Chen J, Schumacher TNM, Schreiber RD, Yeung YA, Djuretic IM. Moynihan KD, et al. Among authors: yeung ya. Cancer Discov. 2024 Apr 2. doi: 10.1158/2159-8290.CD-23-1266. Online ahead of print. Cancer Discov. 2024. PMID: 38563906
An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA, Krishnamoorthy V, Dettling D, Sommer C, Poulsen K, Ni I, Pham A, Chen W, Liao-Chan S, Lindquist K, Chin SM, Chunyk AG, Hu W, Sasu B, Chaparro-Riggers J, Djuretic I. Yeung YA, et al. Mol Ther. 2020 Mar 4;28(3):889-900. doi: 10.1016/j.ymthe.2019.12.014. Epub 2020 Jan 14. Mol Ther. 2020. PMID: 31981494 Free PMC article.
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, Ching K, Yang W, van Loon K, Boor PPC, Rakké YS, Noordam L, Doornebosch P, Grünhagen D, Verhoef K, Polak WG, IJzermans JNM, Ni I, Yeung YA, Salek-Ardakani S, Sprengers D, Kwekkeboom J. Campos Carrascosa L, et al. Among authors: yeung ya. J Immunother Cancer. 2020 Sep;8(2):e000816. doi: 10.1136/jitc-2020-000816. J Immunother Cancer. 2020. PMID: 32900860 Free PMC article.
23 results